Everist Genomics has received the U.S. Clinical Laboratory Improvement Amendment certification required for the company to launch its OncoDefender-CRC assay, a prognostic test for assessing the risk ...
SKY92 and next-generation sequencing (NGS) of bone marrow tumour cells into routine patient care for the first time in Ireland ...
SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for dermatology, hematology, and infectious & inflammatory diseases, announced today ...
Myriad Genetics (MYGN) announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network, NCCN, as an ‘Advanced Tool’ in the fight ...
DNA methylation profiles in whole blood samples from 77 patients with CN-AML in The Cancer Genome Atlas (LAML cohort) were analyzed. Individual 5’-cytosine-phosphate-guanine-3’ (CpG) sites were ...
On Thursday, Telo Genomics Corp (OTC:TDSGF) announced that the manuscript “Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma” was accepted for ...
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...
At the San Antonio Breast Cancer Symposium, researchers presented a study on a multimodal artificial intelligence model that integrated clinical data, pathology-based imaging, and expanded molecular ...
Managing the invisible: Treatment approaches after pathological complete response (pCR) to neoadjuvant chemotherapy in oral cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback